At a University level, UAMC is part of Infla-Med. A research consortium of excellence at the University of Antwerp that conducts fundamental research in the domain of inflammatory diseases by using a multidisciplinary approach.
UAMC is a strong holder in European funding. It coordinates a H2020-MSCA-ITN on training in dry eye disease drug development and participates in a H2020-WIDESPREAD project on development of antibacterials and two H2020-Innovative Medicines Initiatives on the progress of novel assets for tuberculosis and nontubercular mycobacteria. UAMC is also a partner in an IBOF project (ATLANTIS) on Autophagy in inflammation and inflammatory disorders.
In the past, they also participated in several EU funded consortia: a H2020-MSCA-ITN ECMED to study the role of extracellular matrix on epilepsy, an FP7-ITN-OpenMedChem with Glaxo Smith Kline on tuberculosis and an FP7-PDE4NPD on parasitic phosphodiesterases.